Real-world dosing pushes the cost of newer IBD drugs well above their labeled price tags in Saudi Arabia.
Mahmoud H. Mosli, Abdulelah A. Almutairdi, Abdullah M. Alshahrani, et al.
Using a five-year cost model built from expert-informed dosing patterns, this study estimates the financial impact of introducing upadacitinib for ulcerative colitis and risankizumab for Crohn's disease in Saudi Arabia. Because clinicians often dose above labeled recommendations, adjusted dosing raised projected costs substantially over label-based estimates for both conditions, though adding risankizumab modestly lowered overall drug spend for Crohn's disease. The findings suggest real-world prescribing patterns, not just label doses, should inform national budget planning for advanced IBD therapies.
- The question: What would introducing upadacitinib for ulcerative colitis, and risankizumab for Crohn's disease, do to national drug budgets?
- The study: Researchers built a five-year cost model using expert-informed dosing patterns from the clinicians who prescribe these drugs.
- The finding: Because clinicians often dose above the label, adjusted dosing raised projected costs substantially over label-based estimates, for both conditions.
- The nuance: Adding risankizumab did modestly lower overall drug spending for Crohn's disease.
Takeaway: plan national budgets around real-world prescribing patterns, not just labeled doses.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.